Influence of Maxillary Sinus Width on New Bone Formation After Transcrestal Sinus Floor Elevation: A Proof-of-Concept Prospective Cohort Study

PURPOSE: Graft maturation in the maxillary sinus requires adequate angiogenesis and osteoprogenitor cells migration from the surrounding bony walls: the aim of this study was to analyze the correlation between sinus cavity dimensions and new bone formation after transcrestal sinus floor elevation (tSFE). METHODS: Patients needing maxillary sinus augmentation (residual crest height 64 4 mm) were treated with tSFE using xenogeneic granules. Six months later, bone-core biopsies were retrieved for histological analysis in the implant insertion sites. Buccopalatal sinus width (SW) was evaluated on cone beam computed tomography, and correlations between histomorphometric and anatomical parameters were quantified by means of linear regression analysis. RESULTS: Eight consecutive patients underwent tSFE procedures: at 6 months, average percentage of newly formed bone resulted 24.2% \ub1 7.9%. Statistical analysis showed a strong inverse correlation between SW and new bone formation (R = 0.88), and a strong direct correlation between the number of exposed bone walls and new bone formation (R = 0.82). CONCLUSION: Within the limitations of this proof-of-concept study, in which a restricted number of patients were analyzed, tSFE showed more predictable results in narrow than in large sinuses, in terms of new bone formation

Charge response function probed by resonant inelastic x-ray scattering: the signature of electronic gaps of YBa2_2Cu3_3O7−δ_{7-\delta}

In strongly correlated systems the complete determination of the dynamical susceptibility $\chi(\textbf{q}, \omega)$ is of special relevance because of the entwinement of the spin and charge components. Although Resonant Inelastic X-Ray Scattering (RIXS) spectra are directly related to both the charge ($\chi''_c(\textbf{q}, \omega)$) and the spin ($\chi''_s(\textbf{q}, \omega)$) contributions, only the latter has been extensively studied with RIXS so far. Here we show how to extract from RIXS spectra of high-$T_c$ superconducting cuprates relevant properties of $\chi''_c$, such as the presence of the superconducting gap and of the pseudogap. In particular, we exploit the temperature dependence of the Cu L$_3$ edge RIXS spectra of underdoped YBa$_2$Cu$_3$O$_{7-\delta}$ at specific wave-vectors q. The signature of the two gaps is in the departure of the low energy Bosonic excitation continuum from the statistical temperature-dependence. This approach can be immediately used to investigate systematically the nature of the pseudogap in cuprates, thereby taking advantage of the RIXS technique that does not suffer the limitations of surface-sensitive electron spectroscopies. Its extension to other interesting materials is foreseen.Comment: 11 pages, 9 figure

Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency.

Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) age-related withdrawal is very likely to be involved in the aging process and the onset of age-related diseases, giving rise to the question of whether preventing or compensating the decline of these steroids may have endocrine and clinical benefits. The aim of the present trial was to evaluate the endocrine, neuroendocrine and clinical consequences of a long-term (1 year), low-dose (25 mg/day) replacement therapy in a group of aging men who presented the clinical characteristics of partial androgen deficiency (PADAM). Circulating DHEA, DHEAS, androstenedione, total testosterone and free testosterone, dihydrotestosterone (DHT), progesterone, 17-hydroxyprogesterone, allopregnanolone, estrone, estradiol, sex hormone binding globulin (SHBG), cortisol, follicle stimulating hormone (FSH), luteinizing hormone (LH), growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels were evaluated monthly to assess the endocrine effects of the therapy, while beta-endorphin values were used as a marker of the neuroendocrine effects. A Kupperman questionnaire was performed to evaluate the subjective symptoms before and after treatment. The results showed a great modification of the endocrine profile; with the exception of cortisol levels, which remained unchanged, DHEA, DHEAS, androstenedione, total and free testosterone, DHT, progesterone, 17-hydroxyprogesterone, estrone, estradiol, GH, IGF-1 and beta-endorphin levels increased significantly with respect to baseline values, while FSH, LH and SHBG levels showed a significant decrease. The Kupperman score indicated a progressive improvement in mood, fatigue and joint pain. In conclusion, the present study demonstrates that 25 mg/day of DHEA is able to cause significant changes in the hormonal profile and clinical symptoms and can counteract the age-related decline of endocrine and neuroendocrine functions. Restoring DHEA levels to young adult values seems to benefit the age-related decline in physiological functions but, however promising, placebo-controlled trials are required to confirm these preliminary results

New molecular targets in bone metastases

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as " vicious circle," a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results from those in the advanced clinical phases are encouraging and underlined the need to design large randomised clinical trials to validate these results in the next future.Targeting the bone by preventing skeletal related events (SREs) and bone metastases has major clinical impact in improving survival in bone metastatic patients and in preventing disease relapse in adjuvant setting. © 2010 Elsevier Ltd

ASTRI data reduction software in the framework of the Cherenkov Telescope Array

The Cherenkov Telescope Array (CTA) is a worldwide project aimed at building the next-generation groundbased gamma-ray observatory. CTA will be composed of two arrays of telescopes of different sizes, one each in the Northern and Southern hemispheres, to achieve full-sky coverage and a ten-fold improvement in sensitivity with respect to the present-generation facilities. Within the CTA project, the Italian National Institute for Astrophysics (INAF) is developing an end-to-end prototype of one of the CTA Small-Size Telescope's designs with a dual-mirror (SST-2M) Schwarzschild-Couder optics design. The prototype, named ASTRI SST-2M, is located at the INAF "M.C. Fracastoro" observing station in Serra La Nave (Mt. Etna, Sicily) and has started its verification and performance validation phase in fall 2017. A mini-array of (at least) nine ASTRI telescopes has been proposed to be deployed at the CTA southern site, during the pre-production phase, by means of a collaborative effort carried out by institutes from Italy, Brazil, and South Africa. The CTA ASTRI team has developed a complete end-to-end software package for the reduction, up to the final scientific products, of raw data acquired with ASTRI telescopes with the aim of actively contributing to the global ongoing activities for the official data handling system of the CTA observatory. The group is also undertaking a massive production of Monte Carlo simulation data using the same software chain adopted by the CTA Consortium. Both activities are also carried out in the framework of the European H2020-ASTERICS (Astronomy ESFRI and Research Infrastructure Cluster) project. In this work, we present the main components of the ASTRI data reduction software package and report the status of its development. Preliminary results on the validation of both data reduction and telescope simulation chains achieved with real data taken by the prototype and simulations are also discussed

ASTRI SST-2M archive system: a prototype for the Cherenkov Telescope Array

The ASTRI project of the Italian National Institute for Astrophysics (INAF) is developing, in the framework of the Cherenkov Telescope Array (CTA), an end-to-end prototype system based on a dual-mirror small-sized Cherenkov telescope. Data preservation and accessibility are guaranteed by means of the ASTRI Archive System (AAS) that is responsible for both the on-site and off-site archiving of all data produced by the different sub- systems of the so-called ASTRI SST-2M prototype. Science, calibration, and Monte Carlo data together with the dedicated Instrument Response Functions (IRFs) (and corresponding metadata) will be properly stored and organized in different branches of the archive. A dedicated technical data archive (TECH archive) will store the engineering and auxiliary data and will be organized under a parallel database system. Through the use of a physical system archive and a few logical user archives that reflect the different archive use-cases, the AAS has been designed to be independent from any specific data model and storage technology. A dedicated framework to access, browse and download the telescope data has been identified within the proposal handling utility that stores and arranges the information of the observational proposals. The development of the whole archive system follows the requirements of the CTA data archive and is currently carried out by the INAF-OAR & ASI-Science Data Center (ASDC) team. The AAS is fully adaptable and ready for the ASTRI mini-array that, formed of at least nine ASTRI SST-2M telescopes, is proposed to be installed at the CTA southern site

Cherenkov Telescope Array Archive Functional and User Requirements

The scope of the archive system lies on making available and accessible the high level data products of the CTA observatory to the international scientific community. This document describes the high level general functional and user requirements as well as the use cases for the CTA data archive

The On-Site Analysis of the Cherenkov Telescope Array

The Cherenkov Telescope Array (CTA) observatory will be one of the largest ground-based very high-energy gamma-ray observatories. The On-Site Analysis will be the first CTA scientific analysis of data acquired from the array of telescopes, in both northern and southern sites. The On-Site Analysis will have two pipelines: the Level-A pipeline (also known as Real-Time Analysis, RTA) and the level-B one. The RTA performs data quality monitoring and must be able to issue automated alerts on variable and transient astrophysical sources within 30 seconds from the last acquired Cherenkov event that contributes to the alert, with a sensitivity not worse than the one achieved by the final pipeline by more than a factor of 3. The Level-B Analysis has a better sensitivity (not be worse than the final one by a factor of 2) and the results should be available within 10 hours from the acquisition of the data: for this reason this analysis could be performed at the end of an observation or next morning. The latency (in particular for the RTA) and the sensitivity requirements are challenging because of the large data rate, a few GByte/s. The remote connection to the CTA candidate site with a rather limited network bandwidth makes the issue of the exported data size extremely critical and prevents any kind of processing in real-time of the data outside the site of the telescopes. For these reasons the analysis will be performed on-site with infrastructures co-located with the telescopes, with limited electrical power availability and with a reduced possibility of human intervention. This means, for example, that the on-site hardware infrastructure should have low-power consumption. A substantial effort towards the optimization of high-throughput computing service is envisioned to provide hardware and software solutions with high-throughput, low-power consumption at a low-cost.Comment: In Proceedings of the 34th International Cosmic Ray Conference (ICRC2015), The Hague, The Netherlands. All CTA contributions at arXiv:1508.0589

Use of High-Dose Nebulized Colistimethate in Patients with Colistin-Only Susceptible Acinetobacter baumannii VAP: Clinical, Pharmacokinetic and Microbiome Features

(1) Background: Colistin-only susceptible (COS) Acinetobacter baumannii (AB) ventilator-associated pneumonia (VAP) represents a clinical challenge in the Intensive Care Unit (ICU) due to the negligible lung diffusion of this molecule and the low-grade evidence on efficacy of its nebulization. (2) Methods: We conducted a prospective observational study on 134 ICU patients with COS-AB VAP to describe the 'real life' clinical use of high-dose (5 MIU q8) aerosolized colistin, using a vibrating mesh nebulizer. Lung pharmacokinetics and microbiome features were investigated. (3) Results: Patients were enrolled during the COVID-19 pandemic with the ICU presenting a SAPS II of 42 [32-57]. At VAP diagnosis, the median PaO2/FiO(2) was 120 [100-164], 40.3% were in septic shock, and 24.6% had secondary bacteremia. The twenty-eight day mortality was 50.7% with 60.4% and 40.3% rates of clinical cure and microbiological eradication, respectively. We did not observe any drug-related adverse events. Epithelial lining fluid colistin concentrations were far above the CRAB minimal-inhibitory concentration and the duration of nebulized therapy was an independent predictor of microbiological eradication (12 [9.75-14] vs. 7 [4-13] days, OR (95% CI): 1.069 (1.003-1.138), p = 0.039). (4) Conclusions: High-dose and prolonged colistin nebulization, using a vibrating mesh, was a safe adjunctive therapeutic strategy for COS-AB VAP. Its right place and efficacy in this setting warrant investigation in interventional studies